Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials-Reference-Cited by-同舟云学术

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials

Published:2021-06 Issue:6 Volume:9 Page:360-372
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Kahaly George J,Douglas Raymond S,Holt Robert J,Sile Saba,Smith Terry J

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference30 articles.

1. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy;Wiersinga;Lancet Diabetes Endocrinol,2017

2. Clinical manifestations;Dickinson,2017

3. Public health relevance of Graves' orbitopathy;Ponto;J Clin Endocrinol Metab,2013

4. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy;Taylor;Nat Rev Endocrinol,2020

5. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy;Bartalena;Eur Thyroid J,2016

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review;The Laryngoscope;2024-09-13

2. Assessment of Hearing Dysfunction in Patients With Graves’ Disease and Thyroid Eye Disease Without or With Teprotumumab;The Journal of Clinical Endocrinology & Metabolism;2024-08-14

3. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system;Frontiers in Pharmacology;2024-08-09

4. Personalized Medicine in Orbital Surgery;Current Surgery Reports;2024-08-07

5. Long-Term Outcomes following Teprotumumab for Thyroid Eye Disease;Clinical Thyroidology®;2024-08-01